Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-043641
Filing Date
2025-05-15
Accepted
2025-05-15 06:14:31
Documents
38
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0241629-10q_raphael.htm   iXBRL 10-Q 295482
2 FORM OF SUBSCRIPTION AGREEMENT ea024162901ex10-1_raphael.htm EX-10.1 134624
3 CERTIFICATION ea024162901ex31-1_raphael.htm EX-31.1 10004
4 CERTIFICATION ea024162901ex31-2_raphael.htm EX-31.2 9931
5 CERTIFICATION ea024162901ex32-1_raphael.htm EX-32.1 3257
6 CERTIFICATION ea024162901ex32-2_raphael.htm EX-32.2 3098
  Complete submission text file 0001213900-25-043641.txt   1864770

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE raph-20250331.xsd EX-101.SCH 15777
8 XBRL CALCULATION FILE raph-20250331_cal.xml EX-101.CAL 15670
9 XBRL DEFINITION FILE raph-20250331_def.xml EX-101.DEF 70707
10 XBRL LABEL FILE raph-20250331_lab.xml EX-101.LAB 153351
11 XBRL PRESENTATION FILE raph-20250331_pre.xml EX-101.PRE 89697
40 EXTRACTED XBRL INSTANCE DOCUMENT ea0241629-10q_raphael_htm.xml XML 105208
Mailing Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108
Business Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108 702-442-1166
Raphael Pharmaceutical Inc. (Filer) CIK: 0001415397 (see all company filings)

EIN.: 260204284 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-53002 | Film No.: 25948444
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)